Dr. Navada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1190 5th Ave
New York, NY 10029Phone+1 212-241-5520Fax+1 212-348-9233- Is this information wrong?
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Michigan Health SystemResidency, Internal Medicine, 2004 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2007 - 2025
MI State Medical License 2004 - 2007- American Board of Internal Medicine Hematology
Clinical Trials
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Ana...Nishan Sengupta, Dylan Supina, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Rami S Komrokji, Shyamala Navada, Eric Padron, David Sallman> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) ...Yazan Madanat, Michael R Savona, Mikkael A Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Doughert...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- 6 citationsImetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, ra...Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M., Savona, M., Madanat, Y., Díez-Campelo, M., Valcárcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L...> ;Lancet. 2024 Jan 20
- Join now to see all
Abstracts/Posters
- Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)Shyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/_-Catenin Signaling and Downstream Hematopoi...Shyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...Shyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual MeetingDecember 5th, 2016
Other Languages
- French, Kannada
Hospital Affiliations
The Mount Sinai HospitalNew York, New York
Mount Sinai Beth IsraelNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
